VRTX has been inching closer to breaking out of its range state. With Biotech making new highs the stock should have flow tailwinds and any suppression of volatility in the market should be a positive.
- Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis.
- Target Price: $292.00 by CreditSuisse Oct 29, 2020 with multiple buy ratings by different analysts
- Recent Drop from failed study of VX-814 for patients with ALPHA-1 ANTITRYPSIN DEFICIENCY, but still one more study going in same target area...
H&S with a bearishrising narrowing wedge = TROUBLE
Bad combo
OUCH!
From looking at monthly and weekly candles, looks like this one may pull back a bit more
NV is very high on this one. Short interest fairly low considering. I guess the shorties did not catch this pattern on time. Short interest was up 12% today
No recommendation/just an observation
VRTX is basing below the 10WMA and that is a big negative. The positive of this is that the volume action below the 10WMA is drying up, which means that there is a quiet consolidation period that is going on. If this consolidation period starts to show price action that shoots above the 10WMA then there is a potential buy. The 1st buy might be at 285.67 with...
New agreements with Germany and England for new medicines and medical research developments.
We combine the stochastic with the 125 and 40 period moving lines, expect a crossover of both lines within the range and if it is coincident with the stochastic crossing the oversold line up, then we release the long. We can work stretches of 60 points.
